西班牙晚期粘膜黑色素瘤患者的治疗结果:来自真实世界GEM1801研究的结果

IF 1.9 4区 医学 Q3 DERMATOLOGY
Pablo Cerezuela-Fuentes, Carlos Aguado de la Rosa, Guillermo Crespo, Miguel-Ángel Berciano-Guerrero, Ainara Soria, Eva Muñoz-Couselo, Rafael López Castro, Margarita Majem, Pablo Ayala de Miguel, José Luis Manzano, Lorena Bellido, M José Lecumberri, Mónica Corral Subias, José Carlos Villa Guzmán, Berta Hernández, Enrique Espinosa, Teresa Puértolas, Lourdes Gutiérrez Sanz, Javier Medina Martínez, Vicente Palomar Abril, Salvador Martín Algarra, Iván Márquez-Rodas
{"title":"西班牙晚期粘膜黑色素瘤患者的治疗结果:来自真实世界GEM1801研究的结果","authors":"Pablo Cerezuela-Fuentes, Carlos Aguado de la Rosa, Guillermo Crespo, Miguel-Ángel Berciano-Guerrero, Ainara Soria, Eva Muñoz-Couselo, Rafael López Castro, Margarita Majem, Pablo Ayala de Miguel, José Luis Manzano, Lorena Bellido, M José Lecumberri, Mónica Corral Subias, José Carlos Villa Guzmán, Berta Hernández, Enrique Espinosa, Teresa Puértolas, Lourdes Gutiérrez Sanz, Javier Medina Martínez, Vicente Palomar Abril, Salvador Martín Algarra, Iván Márquez-Rodas","doi":"10.1097/CMR.0000000000001062","DOIUrl":null,"url":null,"abstract":"<p><p>Patients with mucosal melanoma have lower survival rates than those with cutaneous melanoma. Recent studies have reported lower mucosal melanoma survival rates with the use of immune checkpoint inhibitors (ICIs). This study analyzed ICI treatment outcomes in patients with mucosal melanoma in a real-world context. The objective response rate, progression-free survival (PFS), and overall survival (OS) after first- and second-line ICI treatments were analyzed in a population of patients with advanced mucosal melanoma included in the observational GEM1801 study in Spain. Univariate Cox regression analysis was used to identify prognostic factors. From 1126 patients included between August 2018 and January 2024, 52 (4.6%) patients with mucosal melanoma were selected, with a median age at advanced stage diagnosis of 70 years; 50% were female. Most patients had an Eastern Cooperative Oncology Group performance status of 0 (48%). Tumors were primarily located in the lower gastrointestinal tract (40%) and the nasal cavity (35%). In the metastatic setting, 32 (62%) patients received ICI. At a median follow-up of 13.7 months, patients receiving ICI had a median PFS and OS of 9.4 [95% confidence interval (CI): 6.6-17.0] and 25.9 (95% CI: 21-not reached) months, respectively, for first-line treatment, and 5.1 (95% CI: 1.9-not reached) and 21.0 (95% CI: 11.1-not reached) months for second-line treatment. The clinical benefit of ICI treatment in mucosal melanoma is in accordance with previous clinical trials but is still limited, highlighting the need for new approaches for this patient population.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study.\",\"authors\":\"Pablo Cerezuela-Fuentes, Carlos Aguado de la Rosa, Guillermo Crespo, Miguel-Ángel Berciano-Guerrero, Ainara Soria, Eva Muñoz-Couselo, Rafael López Castro, Margarita Majem, Pablo Ayala de Miguel, José Luis Manzano, Lorena Bellido, M José Lecumberri, Mónica Corral Subias, José Carlos Villa Guzmán, Berta Hernández, Enrique Espinosa, Teresa Puértolas, Lourdes Gutiérrez Sanz, Javier Medina Martínez, Vicente Palomar Abril, Salvador Martín Algarra, Iván Márquez-Rodas\",\"doi\":\"10.1097/CMR.0000000000001062\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Patients with mucosal melanoma have lower survival rates than those with cutaneous melanoma. Recent studies have reported lower mucosal melanoma survival rates with the use of immune checkpoint inhibitors (ICIs). This study analyzed ICI treatment outcomes in patients with mucosal melanoma in a real-world context. The objective response rate, progression-free survival (PFS), and overall survival (OS) after first- and second-line ICI treatments were analyzed in a population of patients with advanced mucosal melanoma included in the observational GEM1801 study in Spain. Univariate Cox regression analysis was used to identify prognostic factors. From 1126 patients included between August 2018 and January 2024, 52 (4.6%) patients with mucosal melanoma were selected, with a median age at advanced stage diagnosis of 70 years; 50% were female. Most patients had an Eastern Cooperative Oncology Group performance status of 0 (48%). Tumors were primarily located in the lower gastrointestinal tract (40%) and the nasal cavity (35%). In the metastatic setting, 32 (62%) patients received ICI. At a median follow-up of 13.7 months, patients receiving ICI had a median PFS and OS of 9.4 [95% confidence interval (CI): 6.6-17.0] and 25.9 (95% CI: 21-not reached) months, respectively, for first-line treatment, and 5.1 (95% CI: 1.9-not reached) and 21.0 (95% CI: 11.1-not reached) months for second-line treatment. The clinical benefit of ICI treatment in mucosal melanoma is in accordance with previous clinical trials but is still limited, highlighting the need for new approaches for this patient population.</p>\",\"PeriodicalId\":18550,\"journal\":{\"name\":\"Melanoma Research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Melanoma Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/CMR.0000000000001062\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CMR.0000000000001062","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

粘膜黑色素瘤患者的存活率低于皮肤黑色素瘤患者。最近的研究报道,使用免疫检查点抑制剂(ICIs)降低了粘膜黑色素瘤的存活率。本研究分析了现实世界中黏膜黑色素瘤患者的ICI治疗结果。在西班牙GEM1801观察性研究中,分析了一线和二线ICI治疗后的客观缓解率、无进展生存期(PFS)和总生存期(OS)。采用单因素Cox回归分析确定预后因素。从2018年8月至2024年1月纳入的1126例患者中,选择了52例(4.6%)粘膜黑色素瘤患者,晚期诊断的中位年龄为70岁;50%是女性。大多数患者在东部肿瘤合作组的表现状态为0(48%)。肿瘤主要位于下胃肠道(40%)和鼻腔(35%)。在转移情况下,32例(62%)患者接受了ICI。在中位随访13.7个月时,接受ICI的患者一线治疗的中位PFS和OS分别为9.4[95%可信区间(CI): 6.6-17.0]和25.9 (95% CI: 21-未达到)个月,二线治疗的中位PFS和OS分别为5.1 (95% CI: 1.9-未达到)和21.0 (95% CI: 11.1-未达到)个月。ICI治疗粘膜黑色素瘤的临床获益与先前的临床试验一致,但仍然有限,这突出了对这一患者群体的新方法的需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study.

Patients with mucosal melanoma have lower survival rates than those with cutaneous melanoma. Recent studies have reported lower mucosal melanoma survival rates with the use of immune checkpoint inhibitors (ICIs). This study analyzed ICI treatment outcomes in patients with mucosal melanoma in a real-world context. The objective response rate, progression-free survival (PFS), and overall survival (OS) after first- and second-line ICI treatments were analyzed in a population of patients with advanced mucosal melanoma included in the observational GEM1801 study in Spain. Univariate Cox regression analysis was used to identify prognostic factors. From 1126 patients included between August 2018 and January 2024, 52 (4.6%) patients with mucosal melanoma were selected, with a median age at advanced stage diagnosis of 70 years; 50% were female. Most patients had an Eastern Cooperative Oncology Group performance status of 0 (48%). Tumors were primarily located in the lower gastrointestinal tract (40%) and the nasal cavity (35%). In the metastatic setting, 32 (62%) patients received ICI. At a median follow-up of 13.7 months, patients receiving ICI had a median PFS and OS of 9.4 [95% confidence interval (CI): 6.6-17.0] and 25.9 (95% CI: 21-not reached) months, respectively, for first-line treatment, and 5.1 (95% CI: 1.9-not reached) and 21.0 (95% CI: 11.1-not reached) months for second-line treatment. The clinical benefit of ICI treatment in mucosal melanoma is in accordance with previous clinical trials but is still limited, highlighting the need for new approaches for this patient population.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Melanoma Research
Melanoma Research 医学-皮肤病学
CiteScore
3.40
自引率
4.50%
发文量
139
审稿时长
6-12 weeks
期刊介绍: ​​​​​​Melanoma Research is a well established international forum for the dissemination of new findings relating to melanoma. The aim of the Journal is to promote the level of informational exchange between those engaged in the field. Melanoma Research aims to encourage an informed and balanced view of experimental and clinical research and extend and stimulate communication and exchange of knowledge between investigators with differing areas of expertise. This will foster the development of translational research. The reporting of new clinical results and the effect and toxicity of new therapeutic agents and immunotherapy will be given emphasis by rapid publication of Short Communications. ​Thus, Melanoma Research seeks to present a coherent and up-to-date account of all aspects of investigations pertinent to melanoma. Consequently the scope of the Journal is broad, embracing the entire range of studies from fundamental and applied research in such subject areas as genetics, molecular biology, biochemistry, cell biology, photobiology, pathology, immunology, and advances in clinical oncology influencing the prevention, diagnosis and treatment of melanoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信